CF
61 programs · 58 companies
Programs
61
Companies
58
Trials
49
MOAs
39
BTKiCAR-T BCMAALKiPLK4iPD-1iSHP2iJAK1iIL-13iAnti-TauBiTE
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| BMY-3371 | Phase 3 | WRN | ||
| NVO-9087 | Phase 1/2 | Tau | ||
| Sovacapivasertib | Phase 3 | WEE1 | ||
| AMG-2597 | Phase 2/3 | CD38 | ||
| Nirabrutinib | Phase 2/3 | CDK2 | ||
| Talatapinarof | Phase 1/2 | PCSK9 | ||
| ROI-1081 | Phase 1/2 | PI3Kα | ||
| ROI-3353 | Phase 1/2 | PLK4 | ||
| Voxamavacamten | Approved | BET | ||
| AXS-4984 | Preclinical | JAK2 | ||
| ACA-2691 | Phase 3 | BCMA | ||
| Cevizasiran | Phase 1/2 | GPRC5D | ||
| Terainavolisib | Preclinical | FXIa | ||
| Mavutuximab | Approved | APOC3 | ||
| Adagraderotide | Phase 2 | EGFR | ||
| 452-3353 | Preclinical | KRASG12D | ||
| Talafutibatinib | Phase 1/2 | TROP-2 | ||
| Bemabrutinib | Phase 1 | GPRC5D | ||
| Zanulemzoparlimab | NDA/BLA | KRASG12D | ||
| Sotobrutinib | NDA/BLA | BTK | ||
| SWO-IIT-993 | Approved | C5 | ||
| UCS-IIT-264 | Phase 3 | LAG-3 | ||
| Geliinavolisib | NDA/BLA | TIM-3 | ||
| Gelitenlimab | Preclinical | EGFR | ||
| Geliglumide | Phase 1 | PI3Kα | ||
| CAD-8013 | Phase 3 | WEE1 | ||
| CON-4833 | Phase 2/3 | CD20 | ||
| Zorilucimab | NDA/BLA | PSMA | ||
| Pemiosocimab | Phase 1 | PD-L1 | ||
| Ceviosocimab | NDA/BLA | FGFR | ||
| ELO-7744 | Phase 2 | B7-H3 | ||
| Motanaritide | Approved | FLT3 | ||
| Taladerotide | Phase 2/3 | SHP2 | ||
| Ribotinib | Phase 1/2 | CD20 | ||
| Polalucimab | Phase 2 | CDK4/6 | ||
| VAL-3792 | Phase 1/2 | PD-1 | ||
| RYT-9424 | Phase 2/3 | CGRP | ||
| Mirirelsin | Phase 1/2 | IL-13 | ||
| Sovafotisoran | Phase 1 | KIF18A | ||
| LOG-8406 | Phase 3 | SOS1 | ||
| Rilulucimab | NDA/BLA | PI3Kα | ||
| GEN-IIT-381 | Phase 2 | FXIa | ||
| Cevimavacamten | Phase 1/2 | FcRn | ||
| Nidalemzoparlimab | Phase 1 | SOS1 | ||
| 128-2997 | Phase 1/2 | VEGF | ||
| LAU-2489 | Phase 2 | B7-H3 | ||
| Lirazasiran | Phase 3 | KRASG12D | ||
| Taladerotide | Phase 1 | CD38 | ||
| RED-3997 | NDA/BLA | CD3 | ||
| Rimasacituzumab | Phase 3 | C5 | ||
| ORP-8634 | Phase 1/2 | KRASG12D | ||
| MAG-6737 | Preclinical | B7-H3 | ||
| 415-7241 | Phase 1 | HER2 | ||
| Semafutibatinib | Phase 3 | Nectin-4 | ||
| Nidaratamab | Preclinical | AHR | ||
| Lisotapinarof | NDA/BLA | CD38 | ||
| 002-2150 | Phase 2 | GIP-R | ||
| Lisomavacamten | NDA/BLA | IL-17A | ||
| Polacilimab | NDA/BLA | USP1 | ||
| GR-6650 | NDA/BLA | PLK4 | ||
| VEE-457 | Phase 1 | BCL-2 |
Trials (49)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT08091234 | BMY-3371 | Phase 3 | Completed |
| NCT04299458 | Nirabrutinib | Phase 2/3 | Terminated |
| NCT05934025 | ROI-1081 | Phase 1/2 | Not yet recr... |
| NCT08689348 | Voxamavacamten | Approved | Recruiting |
| NCT05088634 | ACA-2691 | Phase 3 | Completed |
| NCT08600240 | ACA-2691 | Phase 3 | Completed |
| NCT07254838 | Cevizasiran | Phase 1/2 | Not yet recr... |
| NCT05650552 | Cevizasiran | Phase 1/2 | Not yet recr... |
| NCT04553564 | Mavutuximab | Approved | Not yet recr... |
| NCT05072310 | Mavutuximab | Approved | Recruiting |
| NCT04174363 | Adagraderotide | Phase 2 | Recruiting |
| NCT06571646 | Talafutibatinib | Phase 1/2 | Recruiting |
| NCT08773286 | Talafutibatinib | Phase 1/2 | Recruiting |
| NCT08809291 | Bemabrutinib | Phase 1 | Active |
| NCT03223131 | Sotobrutinib | NDA/BLA | Terminated |
| NCT04156517 | SWO-IIT-993 | Approved | Completed |
| NCT06947879 | UCS-IIT-264 | Phase 3 | Terminated |
| NCT08399070 | Geliinavolisib | NDA/BLA | Active |
| NCT06558688 | Gelitenlimab | Preclinical | Not yet recr... |
| NCT03582151 | Zorilucimab | NDA/BLA | Completed |